9.12 -0.60 (-6.17%)
After hours: 5:30PM EST
Previous close | 10.10 |
Open | 10.13 |
Bid | 9.31 x 2200 |
Ask | 9.35 x 800 |
Day's range | 9.67 - 10.28 |
52-week range | 3.14 - 33.79 |
Volume | 6,487,375 |
Avg. volume | 10,709,927 |
Market cap | 1.647B |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
Barbuto & Johansson, P.A. (“BARJO”) reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Inovio Pharmaceuticals, Inc. (INO), and appointment of lead plaintiff. The class action, McDermid v. Inovio Pharmaceuticals, Inc., et al., 2:20-cv-01402, was filed in the US District Court for the Eastern District of Pennsylvania on behalf of shareholders who purchased Inovio securities between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”).
NEW YORK, May 11, 2020 -- In a release issued today by The Rosen Law Firm, P.A. under the headline "INO FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds Inovio.